Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00815165 · ClinicalTrials.gov registry record

Cytomegalovirus Cell-Mediated Immunity

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
165
Enrollment target

NCT00815165 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 165 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00815165 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
165 participants
Enrollment target

Study Summary

Cytomegalovirus (CMV) is an important cause of illness and occasional deaths in infants who catch the virus before they are born, in newborns, and in children and adults who have weak immune systems. The purpose of this study is to look at how the CMV vaccine works in the blood. This study is being done along with the main CMV gB/MF59 vaccine study that looks at how the overall body reacts to the vaccine. Participants will include up to 100 healthy adolescent female subjects aged 12 to 17 years who were vaccinated in study 04-039 and 100 subjects that were screened for 04-039 to participate as controls. Study procedures will include up to 6 blood draws taken over a 13 month period. Participation will be about 31 months (unless the patient enrolls into the shedding study).

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2006-06
Est. Completion 2011-08

What the Registry Record Tells You About NCT00815165

The ClinicalTrials.gov registry entry for NCT00815165 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00815165 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00815165 about?

NCT00815165 is a clinical study titled "Cytomegalovirus Cell-Mediated Immunity". Cytomegalovirus (CMV) is an important cause of illness and occasional deaths in infants who catch the virus before they are born, in newborns, and in children and adults who have weak immune systems. The purpose of this study is to look at how the CMV vaccine works in the blood. This study is being ...

What is the current status of trial NCT00815165?

This trial is currently completed. The enrollment target is 165 participants. The study started on 2006-06. Estimated completion is 2011-08.

Who is sponsoring clinical trial NCT00815165?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.